Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219422 · ClinicalTrials.gov registry record · NA
Testing ALERT With GTO in Middle Schools
A NA study of Substance Abuse, sponsored by RAND.
- Recruiting
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05219422: Recruiting NA study of Substance Abuse, sponsored by RAND.
NCT05219422 is a NA study of Substance Abuse that is actively recruiting participants, run by RAND. The registered enrollment target is 42 participants, below the 5,259-participant average among 58 other Substance Abuse trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05219422, a NA study of Substance Abuse, is actively recruiting participants, sponsored by RAND.
- RECRUITING
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
To test the efficacy of Project ALERT with the support enhancement tool, Getting To Outcomes.
Primary Outcome
Alcohol and drug use will be assessed for alcohol, cigarettes, marijuana, e-cigarettes, prescription opioids, and heroin (lifetime, past month, past year use), allowing us to evaluate program effects on ever, past month, and weekly use. We will assess marijuana and nicotine using items to capture nuanced products (e.g., JUUL/vape pens) and include combinations of marijuana/nicotine products to assess co-use, such as using a vaporizer to vape both nicotine e-liquid and cannabis oil. For alcohol,
Conditions Studied
Interventions
- BEHAVIORAL Project ALERT
- BEHAVIORAL Getting to Outcomes
Study Locations (1)
California
- Los Angeles Unified School District - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT05219422 shows while recruiting
NCT05219422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 5,259-participant average among 58 other Substance Abuse trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 2 interventions - of which Project ALERT is the first listed.
NCT05219422 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05219422 about?
NCT05219422 is a clinical study titled "Testing ALERT With GTO in Middle Schools". To test the efficacy of Project ALERT with the support enhancement tool, Getting To Outcomes.
What is the current status of trial NCT05219422?
This trial is currently recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2022-08-30. Estimated completion is 2026-03-31.
What conditions does trial NCT05219422 study?
This clinical trial studies the following conditions: Substance Abuse.
What interventions are being tested in trial NCT05219422?
The interventions under investigation include: Project ALERT (BEHAVIORAL), Getting to Outcomes (BEHAVIORAL).
Who is sponsoring clinical trial NCT05219422?
This trial is sponsored by RAND, which has 78 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219422 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05219422's enrollment target sits among peer trials
42 51st of 58 higher than 8 of 58 other Substance Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
The STop UNhealthy Substance Use Now Trial
RECRUITING · NA
-
The Trans-Led Care Study
RECRUITING · NA
-
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
RECRUITING · NA
-
SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Immigrant Families
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI